Celgene (CELG) early Thursday beat analysts' Q3 expectations and raised its EPS outlook Thursday, sending its shares up 1.5% in early trading. The biotech said sales rose 14% over the year-ago quarter to $1.42 billion, a hair above analysts' consensus of $1.41 billion. Adjusted earnings rose 26% to $1.29 a share, beating consensus by 2 cents. U.S. sales of its main revenue driver, the cancer drug Revlimid, fell a bit short of expectations at $547